×
About 93,383 results

ALLMedicine™ Myocardial Infarction Center

Research & Reviews  31,171 results

Complications from ankle arthrodesis in diabetes-related Charcot foot syndrome.
https://doi.org/10.1016/j.jdiacomp.2021.108071
Journal of Diabetes and Its Complications; Wang BK, Wukich DK et. al.

Oct 23rd, 2021 - Charcot neuroarthropathy (CN) is an inflammatory arthropathy associated with bony destruction, dislocation, and deformity in patients with neuropathy. Surgical procedures involving foot and ankle in CN for deformity correction have been shown to r...

Hemin enhances the cardioprotective effects of mesenchymal stem cell-derived exosomes a...
https://doi.org/10.1186/s12951-021-01077-y 10.1038/s41419-020-03120-6 10.1038/s41569-020-0403-y 10.1038/s41419-019-2061-8 10.1038/s41569-018-0036-6 10.1172/jci95148 10.1016/j.lfs.2020.118199 10.3389/fendo.2020.00280 10.1111/acel.13249 10.1111/acel.13128 10.1016/j.devcel.2021.06.009 10.1038/s41467-020-16312-7 10.1096/fj.201901747RR 10.1186/s13287-020-01881-7 10.7150/thno.28021 10.1155/2018/3290372 10.1186/s13287-019-1522-4 10.1186/s12951-021-00942-0 10.1186/s12951-021-00894-5 10.1093/cvr/cvz139 10.1186/s13287-020-01737-0 10.1111/jcmm.14747 10.1146/annurev.pharmtox.010909.105600 10.1038/cddis.2015.91 10.1080/20013078.2020.1723260 10.1016/j.ebiom.2018.11.056 10.1038/s41467-017-00171-w 10.3389/fncel.2018.00301 10.1038/s41419-018-1019-6 10.1186/s13287-019-1183-3 10.18632/aging.102592 10.1161/circresaha.116.310374 10.1186/s12916-015-0399-z 10.1089/ten.TEB.2014.0300 10.1186/s12951-021-00808-5 10.1038/s41419-020-2545-6 10.1161/circresaha.118.312758 10.1002/biof.1571 10.1038/ncomms8619 10.7150/thno.37181 10.1155/2017/4175353 10.1186/s13578-019-0297-8 10.1007/s13105-021-00784-2:10.1007/s13105-021-00784-2 10.1038/s41467-020-18088-2
Journal of Nanobiotechnology; Zheng H, Liang X et. al.

Oct 23rd, 2021 - Application of mesenchymal stem cell-derived exosomes (MSC-EXO) has emerged as a novel therapeutic strategy for myocardial infarction (MI). Our previous study showed that pretreatment with hemin, a potent heme oxygenase-1 (HO-1) inducer, enhanced ...

Contributions of Systolic and Diastolic Blood Pressures to Cardiovascular Outcomes in t...
https://doi.org/10.1016/j.jacc.2021.08.035
Journal of the American College of Cardiology; Itoga NK, Tawfik DS et. al.

Oct 23rd, 2021 - SBP and DBP have important associations with cardiovascular events, but are seldom considered simultaneously. This study sought to simultaneously analyze systolic blood pressure (SBP) and diastolic blood pressure (DBP) measurements on the associat...

Impact of Periprocedural Myocardial Injury and Infarction Definitions on Long-Term Mort...
https://doi.org/10.1161/CIRCINTERVENTIONS.121.010923
Circulation. Cardiovascular Interventions; Song L, Wang Y et. al.

Oct 23rd, 2021 - The prognostic implications of biomarker elevation following percutaneous coronary intervention (PCI) of chronic total occlusion (CTO) lesions remain controversial. This study assessed the association of periprocedural myocardial injury and clinic...

see more →

Guidelines  37 results

Screening for Hypertension in Adults: US Preventive Services Task Force Reaffirmation R...
https://doi.org/10.1001/jama.2021.4987
JAMA , Krist AH et. al.

Apr 28th, 2021 - Hypertension is a prevalent condition that affects approximately 45% of the adult US population and is the most commonly diagnosed condition at outpatient office visits. Hypertension is a major contributing risk factor for heart failure, myocardia...

Myocardial Infarction Without Obstructive Coronary Artery Disease (MINOCA): A Practical...
https://doi.org/10.1016/j.cpcardiol.2020.100761
Current Problems in Cardiology; Ciliberti G, Compagnucci P et. al.

Dec 29th, 2020 - Myocardial infarction without obstructive coronary artery disease (MINOCA) is defined by the evidence of spontaneous acute myocardial infarction (MI) and angiographic exclusion of coronary stenoses ≥50% in any potential infarct related artery, aft...

2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society Position Statement o...
https://doi.org/10.1016/j.cjca.2020.04.004
The Canadian Journal of Cardiology; Deyell MW, AbdelWahab A et. al.

Jun 17th, 2020 - This Canadian Cardiovascular Society position statement is focused on the management of sustained ventricular tachycardia (VT) and ventricular fibrillation (VF) that occurs in patients with structural heart disease (SHD), including previous myocar...

Management of Acute Myocardial Infarction During the COVID-19 Pandemic: A Position Stat...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7173829
Journal of the American College of Cardiology; Mahmud E, Dauerman HL et. al.

Apr 25th, 2020 - The worldwide pandemic caused by the novel acute respiratory syndrome coronavirus 2 has resulted in a new and lethal disease termed coronavirus disease-2019 (COVID-19). Although there is an association between cardiovascular disease and COVID-19, ...

Clinical Summary: Screening for Cardiovascular Disease Risk With Electrocardiography
https://allmedx.com/USPSTFPDF/cvd-screening-with-ecg-clinical-summary.pdf

Jun 5th, 2018 - Clinical Summary: Screening for Cardiovascular Disease Risk With Electrocardiography Population Adults at low risk of CVD events Adults at intermediate or high risk of CVD events Recommendation Do not screen with resting or exercis...

see more →

Drugs  1,789 results see all →

Clinicaltrials.gov  667 results

To Evaluate the Efficacy and Safety of Hearticelgram®-AMI in Patients With Acute Myocardial Infarction.
https://clinicaltrials.gov/ct2/show/NCT01652209

Oct 22nd, 2021 - We are enrolling a patient who had successful conventional percutaneous coronary intervention after acute myocardial infarction. Patients are allocated to one of three groups (group1=comparator, group2= one dose of hearticellgram-AMI). single dose...

The Effect of Angiotensin Receptor-Neprilysin Inhibition on Cardiac Fibrosis in Patients With HFpEF
https://clinicaltrials.gov/ct2/show/NCT05089539

Oct 22nd, 2021 - Heart failure with preserved ejection fraction (HFpEF) comprises approximately 50% of all heart failure. The effectively therapeutic approaches for HFpEF remain limited. The PARAGON-HF trial found that Angiotensin Receptor-Neprilysin Inhibition (A...

Efficacy of Prolonged Anticoagulation for Primary Prevention of Venous Thromboembolic Disease in Autoimmune Hemolytic Anemia: a Prospective, Phase II, Randomized, Multicenter Study
https://clinicaltrials.gov/ct2/show/NCT05089227

Oct 22nd, 2021 - Autoimmune hemolytic anemia (AIHA) is a rare autoimmune disease (incidence <1/100,000 population) responsible for the destruction of red blood cells by the host immune system, notably through the action of autoantibodies. Apart from complications ...

Dapagliflozin Effects on Cardiovascular Events in Patients With an Acute Heart Attack
https://clinicaltrials.gov/ct2/show/NCT04564742

Oct 21st, 2021 - This is a multicentre, parallel group, event-driven, registry-based randomised controlled trial (R-RCT), double-blind, placebo-controlled phase 3 study in patients without diabetes presenting with myocardial infarction (MI) (ST segment elevation m...

Dapagliflozin Effect on Cardiovascular Outcomes in Haemodialysis for End Stage Renal Disease
https://clinicaltrials.gov/ct2/show/NCT04764097

Oct 21st, 2021 - Cardiovascular disease accounts for more than 50% of end-stage renal disease (ESRD) deaths. The reported cardiovascular death rates in patients receiving dialysis are substantially higher than in the general population. Cardiovascular mortality in...

see more →

News  3,687 results

NICE: Inclisiran for Treating Primary Hypercholesterolaemia or Mixed Dyslipidaemia
https://www.medscape.com/viewarticle/960587

Oct 11th, 2021 - National Institute for Health and Care Excellence (NICE) has issued new guidance which recommends inclisiran as an option for treating primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia as an adjunct to d...

MHRA Updates Safety Information On Tofacitinib
https://www.medscape.com/viewarticle/960411

Oct 7th, 2021 - The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a drug safety update for tofacitinib (Xeljanz) stating that individuals aged >65 years, current or past smokers or individuals with other cardiovascular or malignancy risk f...

Degarelix May Reduce Risk of Cardiovascular Events in Prostate Cancer
https://www.onclive.com/view/degarelix-may-reduce-risk-of-cardiovascular-events-in-prostate-cancer

Oct 6th, 2021 - Susan F. Slovin, MD, PhD Preliminary data suggest that patients with cardiovascular disease being treated for metastatic prostate cancer may experience fewer cardiovascular events when treated with a GnRH antagonist, such as degarelix (Firmagon),...

AR Inhibition Advances Progress in Metastatic Castration-Sensitive Prostate Cancer Paradigm
https://www.onclive.com/view/ar-inhibition-advances-progress-in-metastatic-castration-sensitive-prostate-cancer-paradigm

Oct 6th, 2021 - In recent years, findings from multiple pivotal clinical trials have reshaped the treatment paradigm of metastatic castration-sensitive prostate cancer (mCSPC). Three such trials include the phase 3 STAMPEDE (NCT00268476), LATITUDE (NCT01715285), ...

Genomic Breakthroughs Offer Hope for New Strategies in AML
https://www.onclive.com/view/genomic-breakthroughs-offer-hope-for-new-strategies-in-aml

Oct 6th, 2021 - Hetty Carraway, MD Results of a deep sequencing analysis demonstrated that mutations in 8 high-risk genes are associated with an acute myeloid leukemia (AML) diagnosis. These findings, explained Hetty Carraway, MD, lay the ground work for early d...

see more →

Patient Education  2 results see all →